Barrowcliffe T W, Tydeman M S, Kirkwood T B, Thomas D P
Thromb Haemost. 1983 Oct 31;50(3):690-6.
An international collaborative study has been carried out to establish a reference plasma for Factor VIII-related activities. The freeze-dried reference plasma, coded 80/511, was assayed against fresh normal plasma, local standards and another freeze-dried plasma. There was good agreement between laboratories for the comparison of the two freeze-dried plasmas, but wide variation in the comparison of plasma 80/511 with fresh normal plasma and local standards, indicating the differences in Factor VIII content of local pooled plasmas. There were no significant differences between the one-stage and two-stage assays of VIII:C, or between electroimmunoassay (EIA) and immuno-radiometric (IRMA) assays of VIII:Ag. However, in VIII R:RCoF (ristocetin co-factor) assays, the aggregometry methods gave lower values than the macroscopic and counting methods for the comparison of freeze-dried against fresh normal plasmas. From the combined results of assays against each laboratory's fresh normal plasma, potencies were assigned to plasma 80/511 as follows: VIII:C 0.73 VIIIR:Ag 0.87 International Units VIIIR:RCoF 0.80 per ampoule VIIIC:Ag 0.95. Results from accelerated degradation studies indicated that losses of each VIII-related activity in plasma 80/511, when stored at -20 degrees C, should be less than 0.01% per year, indicating its suitability to serve as a long-term reference preparation. Plasma 80/511 has been established by the WHO Expert Committee on Biological Standardization as the 1st International Reference Preparation for Factor VIII-Related Activities in Plasma.
开展了一项国际合作研究,以建立用于凝血因子VIII相关活性的参考血浆。对编码为80/511的冻干参考血浆,采用新鲜正常血浆、当地标准品及另一种冻干血浆进行了测定。各实验室对两种冻干血浆的比较结果吻合良好,但血浆80/511与新鲜正常血浆及当地标准品比较时差异较大,这表明当地混合血浆中凝血因子VIII含量存在差异。VIII:C的一步法和两步法测定之间,或VIII:Ag的电免疫测定(EIA)和免疫放射测定(IRMA)之间均无显著差异。然而,在VIII R:RCoF(瑞斯托霉素辅因子)测定中,对于冻干血浆与新鲜正常血浆的比较,凝集测定法所得值低于宏观和计数法。根据针对各实验室新鲜正常血浆的测定综合结果,血浆80/511的效价如下:VIII:C 0.73,VIIIR:Ag 0.87国际单位,VIIIR:RCoF每安瓿0.80,VIIIC:Ag 0.95。加速降解研究结果表明,血浆80/511在-20℃储存时,各VIII相关活性每年的损失应小于0.01%,表明其适合作为长期参考制剂。血浆80/511已被世界卫生组织生物标准化专家委员会确立为血浆中凝血因子VIII相关活性的第1国际参考制剂。